12 news items
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK
16 May 24
collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
0nq9nsaazpxgvxioth17a99gl7k357tya7vh
TAK
22 Apr 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
yurzbrbrmxs5e6c29 yw9v18
TAK
18 Apr 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
25ckzrz88l07zmcm83c4dn77kbabwj9cerywo7bulf9papg fr1zb6k89kn
TAK
27 Mar 24
options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality- diverse pipeline. Our employees
wvyauqqdqi7ozijufbgd6v3t7gy2rwhm3xiwxo98am5k2qul8ii7bc2
TAK
26 Mar 24
partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
h4fv16tvuew0rb8wi228eulpdybka0fak5ih2wof0c46pf2d7frl7rf6
TAK
13 Mar 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D
7qxuqjche4isb8
TAK
26 Feb 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
a76pop9v67zkuoy60qi9 bgropojdv8d9ji
TAK
26 Feb 24
of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our
- Prev
- 1
- Next